Latest total revenue for IMAB: $0, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2025
Trailing 12 months ending Jun 2025
As of the most recent data (June 2025), IMAB shows a total revenue of $0. That compares with $-1.8B in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, IMAB's total revenue is now $0 (was $-1.8B) — a 100.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether I-Mab is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. I-Mab is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how IMAB stacks up against individual peers as well.
Tracking IMAB's total revenue over time shows whether I-Mab is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $-1.8B in the prior-year period — up 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has I-Mab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $0) with ownership activity and broader fundamentals.